Antithrombin Market by Formulation (Liquid, Lyophilized), Source (Goat Milk, Human), Type, Route, Application - Global Forecast 2024-2030
Description
Antithrombin Market by Formulation (Liquid, Lyophilized), Source (Goat Milk, Human), Type, Route, Application - Global Forecast 2024-2030
The Antithrombin Market size was estimated at USD 796.09 million in 2023 and expected to reach USD 876.87 million in 2024, at a CAGR 10.24% to reach USD 1,575.32 million by 2030.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Antithrombin Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Antithrombin Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Antithrombin Market, highlighting leading vendors and their innovative profiles. These include Bio-Techne Corporation, BioPharm Laboratories, LLC, CSL Limited, Diapharma Group, Inc., European Medicines Agency, Genesis BioPharma, Grifols, S.A., Kedrion S.p.A., Lee Biosolutions, Inc., LFB USA, Inc., Merck KGaA, Octapharma AG, Scripps Laboratories, Inc., Siemens AG, SK Plasma, Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific Inc., and WebMD, LLC.
Market Segmentation & Coverage
This research report categorizes the Antithrombin Market to forecast the revenues and analyze trends in each of the following sub-markets:
Formulation
Liquid
Goat Milk
Anticoagulant
Oral
Diagnostics
Americas
Argentina
California
Australia
Denmark
The report offers valuable insights on the following aspects:
- Market Penetration: It presents comprehensive information on the market provided by key players.
- Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
- Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
- Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
- Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
- What is the market size and forecast of the Antithrombin Market?
- Which products, segments, applications, and areas should one consider investing in over the forecast period in the Antithrombin Market?
- What are the technology trends and regulatory frameworks in the Antithrombin Market?
- What is the market share of the leading vendors in the Antithrombin Market?
- Which modes and strategic moves are suitable for entering the Antithrombin Market?
Note: PDF & Excel + Online Access - 1 Year
Table of Contents
180 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
- 2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
- 3. Executive Summary
- 4. Market Overview
- 4.1. Introduction
- 4.2. Antithrombin Market, by Region
- 5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Growing occurrence of antithrombin deficiency and increased bleeding during surgeries
- 5.1.1.2. Utilization of rapid diagnostic tests and need for antithrombin
- 5.1.1.3. Increasing awareness of the thrombotic disease among consumers
- 5.1.2. Restraints
- 5.1.2.1. Capital-intensive production of antithrombin
- 5.1.3. Opportunities
- 5.1.3.1. Rising adoption of natural agents in antithrombins
- 5.1.3.2. Technological advancements in the development of cost-effective procedures in the production of antithrombin
- 5.1.4. Challenges
- 5.1.4.1. Limitations of lab testing of antithrombin deficiency
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter’s Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
- 6. Antithrombin Market, by Formulation
- 6.1. Introduction
- 6.2. Liquid
- 6.3. Lyophilized
- 7. Antithrombin Market, by Source
- 7.1. Introduction
- 7.2. Goat Milk
- 7.3. Human
- 8. Antithrombin Market, by Type
- 8.1. Introduction
- 8.2. Anticoagulant
- 8.3. Antiplatelet
- 8.4. Thrombolytic Drugs
- 9. Antithrombin Market, by Route
- 9.1. Introduction
- 9.2. Oral
- 9.3. Parenteral
- 10. Antithrombin Market, by Application
- 10.1. Introduction
- 10.2. Diagnostics
- 10.3. Research
- 10.4. Therapeutics
- 11. Americas Antithrombin Market
- 11.1. Introduction
- 11.2. Argentina
- 11.3. Brazil
- 11.4. Canada
- 11.5. Mexico
- 11.6. United States
- 12. Asia-Pacific Antithrombin Market
- 12.1. Introduction
- 12.2. Australia
- 12.3. China
- 12.4. India
- 12.5. Indonesia
- 12.6. Japan
- 12.7. Malaysia
- 12.8. Philippines
- 12.9. Singapore
- 12.10. South Korea
- 12.11. Taiwan
- 12.12. Thailand
- 12.13. Vietnam
- 13. Europe, Middle East & Africa Antithrombin Market
- 13.1. Introduction
- 13.2. Denmark
- 13.3. Egypt
- 13.4. Finland
- 13.5. France
- 13.6. Germany
- 13.7. Israel
- 13.8. Italy
- 13.9. Netherlands
- 13.10. Nigeria
- 13.11. Norway
- 13.12. Poland
- 13.13. Qatar
- 13.14. Russia
- 13.15. Saudi Arabia
- 13.16. South Africa
- 13.17. Spain
- 13.18. Sweden
- 13.19. Switzerland
- 13.20. Turkey
- 13.21. United Arab Emirates
- 13.22. United Kingdom
- 14. Competitive Landscape
- 14.1. FPNV Positioning Matrix
- 14.2. Market Share Analysis, By Key Player
- 14.3. Competitive Scenario Analysis, By Key Player
- 15. Competitive Portfolio
- 15.1. Key Company Profiles
- 15.1.1. Bio-Techne Corporation
- 15.1.2. BioPharm Laboratories, LLC
- 15.1.3. CSL Limited
- 15.1.4. Diapharma Group, Inc.
- 15.1.5. European Medicines Agency
- 15.1.6. Genesis BioPharma
- 15.1.7. Grifols, S.A.
- 15.1.8. Kedrion S.p.A.
- 15.1.9. Lee Biosolutions, Inc.
- 15.1.10. LFB USA, Inc.
- 15.1.11. Merck KGaA
- 15.1.12. Octapharma AG
- 15.1.13. Scripps Laboratories, Inc.
- 15.1.14. Siemens AG
- 15.1.15. SK Plasma
- 15.1.16. Takeda Pharmaceutical Company Limited
- 15.1.17. Thermo Fisher Scientific Inc.
- 15.1.18. WebMD, LLC
- 15.2. Key Product Portfolio
- 16. Appendix
- 16.1. Discussion Guide
- 16.2. License & Pricing
- FIGURE 1. ANTITHROMBIN MARKET RESEARCH PROCESS
- FIGURE 2. ANTITHROMBIN MARKET SIZE, 2023 VS 2030
- FIGURE 3. ANTITHROMBIN MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. ANTITHROMBIN MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. ANTITHROMBIN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. ANTITHROMBIN MARKET DYNAMICS
- FIGURE 7. ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2023 VS 2030 (%)
- FIGURE 8. ANTITHROMBIN MARKET SIZE, BY FORMULATION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. ANTITHROMBIN MARKET SIZE, BY SOURCE, 2023 VS 2030 (%)
- FIGURE 10. ANTITHROMBIN MARKET SIZE, BY SOURCE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. ANTITHROMBIN MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
- FIGURE 12. ANTITHROMBIN MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. ANTITHROMBIN MARKET SIZE, BY ROUTE, 2023 VS 2030 (%)
- FIGURE 14. ANTITHROMBIN MARKET SIZE, BY ROUTE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
- FIGURE 16. ANTITHROMBIN MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. AMERICAS ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 18. AMERICAS ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. UNITED STATES ANTITHROMBIN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 20. UNITED STATES ANTITHROMBIN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 21. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 22. ASIA-PACIFIC ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 24. EUROPE, MIDDLE EAST & AFRICA ANTITHROMBIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 25. ANTITHROMBIN MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 26. ANTITHROMBIN MARKET SHARE, BY KEY PLAYER, 2023
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
